| Year |
Citation |
Score |
| 2024 |
Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, Pecci F, Di Federico A, Venkatraman D, Barrichello AP, Gandhi M, ... ... Cherniack AD, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300580. PMID 38207230 DOI: 10.1200/JCO.23.00580 |
0.745 |
|
| 2023 |
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, ... ... Cherniack AD, et al. Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 8321. PMID 38097580 DOI: 10.1038/s41467-023-44124-y |
0.733 |
|
| 2023 |
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, ... ... Cherniack AD, et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 7496. PMID 37980405 DOI: 10.1038/s41467-023-43324-w |
0.751 |
|
| 2023 |
Groves A, Ward A, Li YY, Lazo de la Vega L, Nag A, Forrest SJ, Gupta HV, Thorner AR, Meyerson M, Kamihara J, Cherniack AD, Janeway KA. Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatric Blood & Cancer. e30643. PMID 37596911 DOI: 10.1002/pbc.30643 |
0.754 |
|
| 2023 |
Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, Cohen EF, Tolstorukov M, Andrews E, Brais LK, da Silva A, Perez K, Rubinson DA, Surana R, Giannakis M, ... ... Cherniack AD, et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37463056 DOI: 10.1158/1078-0432.CCR-22-3930 |
0.743 |
|
| 2023 |
Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, ... ... Cherniack AD, et al. Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37247843 DOI: 10.1016/j.jtho.2023.05.019 |
0.741 |
|
| 2023 |
Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, ... ... Cherniack AD, et al. Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37097610 DOI: 10.1158/1078-0432.CCR-22-3413 |
0.753 |
|
| 2022 |
Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, ... Cherniack AD, et al. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. Jco Precision Oncology. 6: e2200390. PMID 36446043 DOI: 10.1200/PO.22.00390 |
0.741 |
|
| 2022 |
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, ... ... Cherniack AD, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine. PMID 35739269 DOI: 10.1038/s41591-022-01856-6 |
0.732 |
|
| 2022 |
Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, ... ... Cherniack AD, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Jama Oncology. PMID 35708671 DOI: 10.1001/jamaoncol.2022.1981 |
0.753 |
|
| 2021 |
Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, ... ... Cherniack AD, et al. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery. PMID 33926920 DOI: 10.1158/2159-8290.CD-20-1669 |
0.755 |
|
| 2021 |
Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33845210 DOI: 10.1016/j.jtho.2021.03.024 |
0.767 |
|
| 2020 |
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. PMID 32472114 DOI: 10.1038/S41591-020-0839-Y |
0.349 |
|
| 2020 |
Oak N, Cherniack AD, Mashl RJ, Hirsch FR, Ding L, Beroukhim R, Gümüş ZH, Plon SE, Huang KL. Ancestry-specific predisposing germline variants in cancer. Genome Medicine. 12: 51. PMID 32471518 DOI: 10.1186/S13073-020-00744-3 |
0.338 |
|
| 2020 |
Nichols CA, Gibson WJ, Brown MS, Kosmicki JA, Busanovich JP, Wei H, Urbanski LM, Curimjee N, Berger AC, Gao GF, Cherniack AD, Dhe-Paganon S, Paolella BR, Beroukhim R. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nature Communications. 11: 2517. PMID 32433464 DOI: 10.1038/S41467-020-16399-Y |
0.373 |
|
| 2020 |
Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, ... ... Cherniack AD, et al. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 37: 639-654.e6. PMID 32396860 DOI: 10.1016/J.Ccell.2020.04.012 |
0.421 |
|
| 2020 |
Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32332016 DOI: 10.1158/1078-0432.Ccr-19-3529 |
0.42 |
|
| 2020 |
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, ... ... Cherniack AD, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 580: 517-523. PMID 32322066 DOI: 10.1038/S41586-020-2209-9 |
0.376 |
|
| 2020 |
Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, ... ... Cherniack AD, et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research. PMID 32321774 DOI: 10.1158/2326-6066.Cir-19-0866 |
0.401 |
|
| 2020 |
Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32171752 DOI: 10.1016/J.Annonc.2020.02.017 |
0.342 |
|
| 2020 |
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, ... Cherniack AD, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034073 DOI: 10.1158/1078-0432.Ccr-19-3608 |
0.327 |
|
| 2020 |
Wu X, Schnitzler GR, Gao GF, Diamond B, Baker AR, Kaplan B, Williamson K, Westlake L, Lorrey S, Lewis TA, Garvie CW, Lange M, Hayat S, Seidel H, Doench J, ... Cherniack AD, et al. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. The Journal of Biological Chemistry. PMID 32005668 DOI: 10.1074/Jbc.Ra119.011191 |
0.388 |
|
| 2020 |
Cleary JM, Raghavan S, Li YY, Spurr L, Wu Q, Shi L, Brais LK, Odhiambo Z, Goyal L, Patel AK, Shinagare AB, Clancy TE, Shapiro G, Cerami E, Sellers WR, ... ... Cherniack AD, et al. Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 38: 567-567. DOI: 10.1200/Jco.2020.38.4_Suppl.567 |
0.381 |
|
| 2020 |
Ricciuti B, Arbour KC, Lin JJ, Vokes N, Hoojghan AV, Li YY, Cherniack AD, Recondo G, Lamberti G, Venkatraman D, Rizvi H, Egger JV, Plodkowski AJ, Khosrowjerdi S, Digumarthy SR, et al. Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15113 |
0.375 |
|
| 2020 |
Kabraji SK, Spurr LF, Hughes ME, Li YY, Leone JP, Garrido-Castro AC, Barroso-Sousa R, Files J, Kirkner G, Johnson BE, Winer EP, Cherniack AD, Lin NU. Genomic profiling of breast cancer brain metastases reveals targetable alterations. Journal of Clinical Oncology. 38: 2525-2525. DOI: 10.1200/Jco.2020.38.15_Suppl.2525 |
0.35 |
|
| 2020 |
Marinoff A, Spurr LF, Doan D, Corson L, Ward A, Li YY, Cherniack AD, Janeway KA. Characterizing the landscape of genomic variants in high-risk pediatric osteosarcoma. Journal of Clinical Oncology. 38: 11530-11530. DOI: 10.1200/Jco.2020.38.15_Suppl.11530 |
0.304 |
|
| 2020 |
Taylor AM, Jain S, Shih J, Cherniack AD, Beroukhim R, Meyerson M. Abstract A44: Functional models of chromosome arm-level aneuploidies in cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A44 |
0.35 |
|
| 2020 |
Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Kalekar RL, Krill-Burger JM, Hong AL, Kugener G, Kalfon J, Yang A, Yuan C, Dumont N, Gonzalez A, Abdusamad M, ... ... Cherniack AD, et al. Abstract LB-053: VPS4A is a synthetic lethal target in VPS4B-deficient cancers due to co-deletion with SMAD4 Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-053 |
0.428 |
|
| 2020 |
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu B, Bohrson CL, Cortes-Ciriano I, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, ... ... Cherniack A, et al. Abstract 5705: Mechanisms and therapeutic implications of hypermutation in gliomas Cancer Research. 80: 5705-5705. DOI: 10.1158/1538-7445.Am2020-5705 |
0.407 |
|
| 2020 |
Spurr LF, Lamberti G, Li YY, Ricciuti B, Recondo G, Umeton R, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Abstract 5668: Genomic correlates of PD-L1 expression are associated with response to immunotherapy in non-small cell lung cancer Cancer Research. 80: 5668-5668. DOI: 10.1158/1538-7445.Am2020-5668 |
0.334 |
|
| 2019 |
Chen H, Carrot-Zhang J, Zhao Y, Hu H, Freeman SS, Yu S, Ha G, Taylor AM, Berger AC, Westlake L, Zheng Y, Zhang J, Ramachandran A, Zheng Q, Pan Y, ... ... Cherniack AD, et al. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nature Communications. 10: 5472. PMID 31784532 DOI: 10.1038/S41467-019-13460-3 |
0.385 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Cherniack AD, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243 |
0.316 |
|
| 2019 |
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, ... ... Cherniack AD, et al. The Immune Landscape of Cancer. Immunity. 51: 411-412. PMID 31433971 DOI: 10.1016/J.Immuni.2019.08.004 |
0.316 |
|
| 2019 |
Gao GF, Parker JS, Reynolds SM, Silva TC, Wang LB, Zhou W, Akbani R, Bailey M, Balu S, Berman BP, Brooks D, Chen H, Cherniack AD, Demchok JA, Ding L, et al. Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data. Cell Systems. 9: 24-34.e10. PMID 31344359 DOI: 10.1016/J.Cels.2019.06.006 |
0.317 |
|
| 2019 |
Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Cherniack AD, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3 |
0.368 |
|
| 2019 |
Greulich H, Cherniack AD. Genetic clues can be used to predict whether early-stage cancer will form an invasive tumour. Nature. 566: 336-337. PMID 30778180 DOI: 10.1038/D41586-019-00567-2 |
0.349 |
|
| 2019 |
Smithy JW, Hwang DH, Li YY, Spurr L, Cherniack AD, Sholl LM, Awad MM. Changes in tumor mutational burden in serially biopsied non-small cell lung cancer. Journal of Clinical Oncology. 37: e14286-e14286. DOI: 10.1200/Jco.2019.37.15_Suppl.E14286 |
0.401 |
|
| 2019 |
Garrido-Castro AC, Spurr L, Hughes ME, Li YY, Cherniack AD, Bychkovsky BL, Barroso-Sousa R, Lascio SD, Files J, Kumari P, Cerami E, Krop IE, MacConaill LE, Lindeman NI, Rollins BJ, et al. Genomic landscape of de novo stage IV breast cancer. Journal of Clinical Oncology. 37: 1022-1022. DOI: 10.1200/Jco.2019.37.15_Suppl.1022 |
0.345 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... ... Cherniack A, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14 |
0.33 |
|
| 2019 |
Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Lascio SD, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, et al. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-01 |
0.403 |
|
| 2019 |
Sabedot TS, Cassel SH, Gao GF, Lareau CA, Cherniack A, Lazar A, Kadoch C, Noushmehr H. Abstract 907: Bioinformatic method to define epigenetically regulated enhancer elements associated with cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-907 |
0.302 |
|
| 2019 |
Touat M, Li Y, Boynton A, Spurr L, Iorgulescu B, Birzu C, Pal S, Ferrer-Luna R, Geduldig J, Bellamy C, Younan N, Baldini C, Verreault M, Guillerm E, Ammari S, ... ... Cherniack A, et al. DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS Neuro-Oncology. 21: vi73-vi73. DOI: 10.1093/Neuonc/Noz175.296 |
0.369 |
|
| 2019 |
Touat M, Li Y, Boynton A, Spurr L, Iorglescu B, Geduldig J, Birzu C, Lim Fat M, Santagata S, Coulet F, Beuvon F, Mokhtari K, Giry M, Block S, Guillerm E, ... ... Cherniack A, et al. OS9.1 Clinical significance of hypermutation in gliomas Neuro-Oncology. 21: iii18-iii18. DOI: 10.1093/Neuonc/Noz126.059 |
0.351 |
|
| 2019 |
Taylor A, Shih J, Ha G, Gao G, Zhang X, Berger A, Cherniack A, Beroukhim R, Meyerson M. MS12.02 Genomic and Functional Approaches to Understanding Cancer Aneuploidy Journal of Thoracic Oncology. 14: S179. DOI: 10.1016/J.Jtho.2019.08.355 |
0.318 |
|
| 2018 |
Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, Ivan AP, Buchumenski I, Berger AC, Goldstein JT, Cherniack AD, Vazquez F, Tsherniak A, Levanon EY, Hahn WC, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nature Communications. 9: 5450. PMID 30575730 DOI: 10.1038/S41467-018-07824-4 |
0.399 |
|
| 2018 |
Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, et al. Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30442683 DOI: 10.1158/1078-0432.Ccr-18-0452 |
0.389 |
|
| 2018 |
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proceedings of the National Academy of Sciences of the United States of America. PMID 30352856 DOI: 10.1073/Pnas.1803177115 |
0.341 |
|
| 2018 |
Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman DI, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, ... ... Cherniack AD, et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery. PMID 30322867 DOI: 10.1158/2159-8290.Cd-18-0804 |
0.418 |
|
| 2018 |
Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, ... ... Cherniack AD, et al. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems. PMID 30268436 DOI: 10.1016/J.Cels.2018.08.010 |
0.346 |
|
| 2018 |
Viswanathan SR, Nogueira MF, Buss CG, Krill-Burger JM, Wawer MJ, Malolepsza E, Berger AC, Choi PS, Shih J, Taylor AM, Tanenbaum B, Pedamallu CS, Cherniack AD, Tamayo P, Strathdee CA, et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nature Genetics. PMID 29955178 DOI: 10.1038/S41588-018-0155-3 |
0.378 |
|
| 2018 |
Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, ... ... Cherniack AD, et al. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Reports. 23: 3392-3406. PMID 29898407 DOI: 10.1016/J.Celrep.2018.05.039 |
0.377 |
|
| 2018 |
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, ... ... Cherniack AD, et al. The Immune Landscape of Cancer. Immunity. PMID 29628290 DOI: 10.1016/J.Immuni.2018.03.023 |
0.39 |
|
| 2018 |
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 173: 400-416.e11. PMID 29625055 DOI: 10.1016/J.Cell.2018.02.052 |
0.382 |
|
| 2018 |
Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 173: 355-370.e14. PMID 29625052 DOI: 10.1016/J.Cell.2018.03.039 |
0.397 |
|
| 2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Cherniack AD, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035 |
0.423 |
|
| 2018 |
Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, ... ... Cherniack AD, et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 173: 305-320.e10. PMID 29625049 DOI: 10.1016/J.Cell.2018.03.033 |
0.424 |
|
| 2018 |
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 173: 291-304.e6. PMID 29625048 DOI: 10.1016/J.Cell.2018.03.022 |
0.362 |
|
| 2018 |
Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, et al. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. PMID 29622466 DOI: 10.1016/J.Ccell.2018.03.010 |
0.413 |
|
| 2018 |
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Cherniack AD, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014 |
0.417 |
|
| 2018 |
Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. PMID 29622463 DOI: 10.1016/J.Ccell.2018.03.007 |
0.398 |
|
| 2018 |
Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports. 23: 239-254.e6. PMID 29617664 DOI: 10.1016/J.Celrep.2018.03.076 |
0.422 |
|
| 2018 |
Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports. 23: 194-212.e6. PMID 29617660 DOI: 10.1016/J.Celrep.2018.03.063 |
0.352 |
|
| 2018 |
Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports. 23: 172-180.e3. PMID 29617658 DOI: 10.1016/J.Celrep.2018.03.046 |
0.375 |
|
| 2018 |
Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems. 6: 282-300.e2. PMID 29596783 DOI: 10.1016/J.Cels.2018.03.003 |
0.438 |
|
| 2018 |
Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, ... ... Cherniack AD, et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 33: 244-258.e10. PMID 29438696 DOI: 10.1016/J.Ccell.2018.01.003 |
0.374 |
|
| 2018 |
Liu J, Lichtenberg T, Hoadley K, Cherniack A, Poisson L, Kovatich A, Benz C, Thorsson V, Shriver C, Hu H. Abstract P3-16-01: Using the new pan-cancer clinical data resource (TCGA-CDR) to identify breast cancer genomic correlates associating with different survival outcome endpoints Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-16-01 |
0.366 |
|
| 2018 |
Korkut A, Zaidi S, Kanchi R, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Schultz A, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, ... ... Cherniack AD, et al. Abstract 3413: A pan-cancer atlas of genomic, epigenomic and transcriptomic alterations in the TGF-β pathway Cancer Research. 78: 3413-3413. DOI: 10.1158/1538-7445.Am2018-3413 |
0.393 |
|
| 2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, Dimitriadoy S, Liu DL, Kantheti HS, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, ... ... Cherniack AD, et al. Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas Cancer Research. 78: 3302-3302. DOI: 10.1158/1538-7445.Am2018-3302 |
0.436 |
|
| 2018 |
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H. Abstract 3287: An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics Cancer Research. 78: 3287-3287. DOI: 10.1158/1538-7445.Am2018-3287 |
0.378 |
|
| 2018 |
Nichols CA, Paolella BR, Gibson WJ, Brown MS, Urbanski LM, Kosmicki JA, Busanovich JP, Berger AC, Gao GF, Cherniack AD, Beroukhim R. Abstract 3003: Loss of heterozygosity of essential genes represents a novel class of cancer vulnerabilities Cancer Research. 78: 3003-3003. DOI: 10.1158/1538-7445.Am2018-3003 |
0.368 |
|
| 2018 |
Taylor AM, Zhang X, Shih J, Ha G, Gao GF, Berger AC, Cherniack AD, Beroukhim R, Meyerson M. Abstract 3002: Genome engineering approaches to generate models of chromosome arm-level cancer aneuploidy Cancer Research. 78: 3002-3002. DOI: 10.1158/1538-7445.Am2018-3002 |
0.336 |
|
| 2017 |
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. PMID 28988769 DOI: 10.1016/J.Cell.2017.09.007 |
0.352 |
|
| 2017 |
Zhang X, Choi PS, Francis JM, Gao GF, Campbell JD, Ramachandran A, Mitsuishi Y, Ha G, Shih J, Vazquez F, Tsherniak A, Taylor AM, Zhou J, Wu Z, Berger AC, ... ... Cherniack AD, et al. Somatic super-enhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor. Cancer Discovery. PMID 28963353 DOI: 10.1158/2159-8290.Cd-17-0532 |
0.436 |
|
| 2017 |
Goldstein JT, Berger AC, Shih J, Duke FF, Furst L, Kwiatkowski DJ, Cherniack AD, Meyerson M, Strathdee CA. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Research. PMID 28923856 DOI: 10.1158/0008-5472.Can-17-1701 |
0.408 |
|
| 2017 |
Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, ... ... Cherniack AD, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 32: 204-220.e15. PMID 28810145 DOI: 10.1016/J.Ccell.2017.07.003 |
0.335 |
|
| 2017 |
Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, ... ... Cherniack AD, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 19: 2878-2880. PMID 28658632 DOI: 10.1016/J.Celrep.2017.06.008 |
0.308 |
|
| 2017 |
Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, Sisson KA, Koeman J, Weisenberger DJ, Cottingham SL, DeRoos ST, Devinsky O, Winn ME, Cherniack AD, Shen H, et al. The genomic landscape of tuberous sclerosis complex. Nature Communications. 8: 15816. PMID 28643795 DOI: 10.1038/Ncomms15816 |
0.356 |
|
| 2017 |
Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, Um H, Ko WR, Lee BI, Kwon SY, Ryu SW, Kwon CH, Park DY, Lee JH, Lee SI, ... ... Cherniack AD, et al. Sporadic Early-onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations but Low Frequency of Somatic RHOA Mutations Compared with Late-onset Cancers. Gastroenterology. PMID 28522256 DOI: 10.1053/J.Gastro.2017.05.012 |
0.327 |
|
| 2017 |
Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. Jama Oncology. PMID 28472234 DOI: 10.1001/Jamaoncol.2017.0595 |
0.348 |
|
| 2017 |
Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, ... ... Cherniack AD, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 18: 2780-2794. PMID 28297679 DOI: 10.1016/J.Celrep.2017.02.033 |
0.375 |
|
| 2017 |
Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 31: 411-423. PMID 28292439 DOI: 10.1016/J.Ccell.2017.02.010 |
0.412 |
|
| 2017 |
Lerner SP, Robertson G, Kim J, Cherniack A, Guo G, Akbani R, Kanchi RS, Hoadley KA, Hinoue T, Laird PW, Al-Ahmadie H, Bellmunt J, Castro M, Gordenin D, Mills GB, et al. Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. Journal of Clinical Oncology. 35: 4500-4500. DOI: 10.1200/Jco.2017.35.15_Suppl.4500 |
0.387 |
|
| 2017 |
Meyers RM, Aguirre AJ, Weir BA, Vazquez F, Zhang C, Ben-David U, Cook A, Ha G, Harrington WF, Doshi M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, ... ... Cherniack AD, et al. Abstract B39: Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B39 |
0.38 |
|
| 2017 |
Huo D, Hu H, Rhie S, Gamazon E, Cherniack A, Liu J, Yoshimatsu T, Pitt J, Hoadley K, Troester M, Ru Y, Lichtenberg T, Sturtz L, Shelley C, Mills G, et al. Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-05-11 |
0.372 |
|
| 2016 |
Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. PMID 27348297 DOI: 10.1038/Ng.3602 |
0.433 |
|
| 2016 |
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, ... ... Cherniack AD, et al. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery. PMID 27260156 DOI: 10.1158/2159-8290.Cd-16-0154 |
0.346 |
|
| 2016 |
Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports. 6: 25521. PMID 27160768 DOI: 10.1038/Srep25521 |
0.369 |
|
| 2016 |
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, ... ... Cherniack AD, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics. PMID 27158780 DOI: 10.1038/Ng.3564 |
0.314 |
|
| 2016 |
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, ... ... Cherniack AD, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164: 550-563. PMID 26824661 DOI: 10.1016/J.Cell.2015.12.028 |
0.342 |
|
| 2016 |
Lerner SP, Kim J, Kwiatkowski DJ, Getz G, Weinstein JN, Cherniack A, Guo G, Akbani R, Hoadley KA, Kim WY, Robertson G, Mungall AJ, Hinoue T, Laird PW, Al-Ahmadie H, et al. Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. Journal of Clinical Oncology. 34: 405-405. DOI: 10.1200/Jco.2016.34.2_Suppl.405 |
0.406 |
|
| 2016 |
Thompson E, Asmann Y, Su X, Ellis M, Shao J, Hu Y, White K, Cherniack A, Hoadley K, Serie D, Perez E, Perou C. Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S4-02 |
0.382 |
|
| 2016 |
Weinstein JN, Lerner SP, Kwiatkowski DJ, Getz G, Kim J, Al-ahmadie HA, Cherniack AD, Guo G, Akbani R, Hoadley KA, Kim WY, Robertson G, Mungall AJ, Hinoue T, Laird PW, et al. Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project Cancer Research. 76: 128-128. DOI: 10.1158/1538-7445.Am2016-128 |
0.451 |
|
| 2015 |
Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, Meyerson M. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nature Genetics. PMID 26656844 DOI: 10.1038/Ng.3470 |
0.422 |
|
| 2015 |
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, ... ... Cherniack AD, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 163: 506-19. PMID 26451490 DOI: 10.1016/J.Cell.2015.09.033 |
0.391 |
|
| 2015 |
Murray B, Albiges L, Van Allen EM, Cherniack A, Fay AP, Meyerson M, Choueiri TK. Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification. Journal of Clinical Oncology. 33: 4564-4564. DOI: 10.1200/Jco.2015.33.15_Suppl.4564 |
0.411 |
|
| 2015 |
Albiges L, Murray B, Brooks A, Cherniack A, Berger A, Creighton CJ, Ricketts C, Bottaro DP, Srinivasan R, Schmidt LS, Meyerson M, Spellman P, Linehan WM, Choueiri TK. Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. Journal of Clinical Oncology. 33: 4521-4521. DOI: 10.1200/Jco.2015.33.15_Suppl.4521 |
0.392 |
|
| 2015 |
Ciriello G, Gatza ML, Hoadley KA, Zhang H, Rhie SK, Bowlby R, Wilkerson MD, Kandoth C, McLellan M, Cherniack A, Laird PW, Sander C, King TA, Perou CM. Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S2-04 |
0.442 |
|
| 2015 |
Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Bajorin DF, Rosenberg JE, Czerniak B, et al. Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project Cancer Research. 75: 2969-2969. DOI: 10.1158/1538-7445.Am2015-2969 |
0.341 |
|
| 2015 |
Barthel FP, Ceccarelli M, Malta TM, Sabedot TS, Salama SR, Pagnotta SM, Murray BA, Morozova O, Newton Y, Brat DJ, Cherniack AD, Zhang H, Poisson L, Cooper L, Rabadan R, et al. GENO-06A PAN-GLIOMA CHARACTERIZATION OF GENOMIC, EPIGENOMIC AND TRANSCRIPTOMIC ACTIVITIES REVEALS NOVEL RELATIONSHIPS BETWEEN HISTOLOGICAL SUBTYPES AND MOLECULAR SIGNATURES Neuro-Oncology. 17: v92.2-v92. DOI: 10.1093/Neuonc/Nov215.06 |
0.378 |
|
| 2014 |
Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 18661-6. PMID 25512530 DOI: 10.1073/Pnas.1412228112 |
0.37 |
|
| 2014 |
Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 26: 319-30. PMID 25155756 DOI: 10.1016/J.Ccr.2014.07.014 |
0.408 |
|
| 2014 |
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 158: 929-44. PMID 25109877 DOI: 10.1016/J.Cell.2014.06.049 |
0.402 |
|
| 2014 |
Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, ... ... Cherniack AD, et al. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 134: 599-606. PMID 24995579 DOI: 10.1016/J.Ygyno.2014.06.026 |
0.335 |
|
| 2014 |
Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, Cherniack AD, Kim J, Pedamallu CS, Noble MS, Al-Ahmadie HA, et al. Comprehensive molecular characterization of urothelial bladder carcinoma Nature. 507: 315-322. PMID 24476821 DOI: 10.1038/Nature12965 |
0.411 |
|
| 2014 |
Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 506: 371-5. PMID 24390348 DOI: 10.1038/Nature12881 |
0.329 |
|
| 2014 |
Rosenberg JE, Kim J, Cherniack A, Sougnez C, Meyerson M, Getz G, Weinstein JN, Lerner SP, Kwiatkowski DJ. Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis. Journal of Clinical Oncology. 32: 285-285. DOI: 10.1200/Jco.2014.32.4_Suppl.285 |
0.431 |
|
| 2014 |
Berger AH, Brooks AN, Imielinski M, Cherniack A, Duke F, Kaplan N, Wala J, Meyerson M. Abstract PR08:NF1,MET, andRIT1mutations are RAS-pathway driver events in lung adenocarcinoma Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr08 |
0.414 |
|
| 2014 |
Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Rosenberg JE, Bajorin DF, Czerniak B, et al. Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update Cancer Research. 74: 987-987. DOI: 10.1158/1538-7445.Am2014-987 |
0.457 |
|
| 2014 |
Ojesina AI, Murray B, Bjorge L, Woie K, Krakstad C, Lichtenstein L, Pedamallu CS, Taylor-Weiner A, Freeman SS, Cherniack AD, Lawrence MS, Cibulskis K, Carter SL, Walline H, Carey TE, et al. Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer Cancer Research. 74: 4692-4692. DOI: 10.1158/1538-7445.Am2014-4692 |
0.402 |
|
| 2013 |
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discovery. 3: 1355-63. PMID 24078774 DOI: 10.1158/2159-8290.Cd-13-0310 |
0.364 |
|
| 2013 |
Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J, Mermel CH, Sougnez C, Gabriel SB, Hernandez B, Shen H, Laird PW, et al. Pan-cancer patterns of somatic copy number alteration. Nature Genetics. 45: 1134-40. PMID 24071852 DOI: 10.1038/Ng.2760 |
0.438 |
|
| 2013 |
Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (New York, N.Y.). 340: 1100-6. PMID 23723238 DOI: 10.1126/Science.1232044 |
0.373 |
|
| 2013 |
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 497: 67-73. PMID 23636398 DOI: 10.1038/Nature12113 |
0.375 |
|
| 2013 |
Pashtan IM, Neuberg DS, Beroukhim R, Salvesen HB, Cherniack A. Distinct copy number alteration patterns as prognostic of endometrial cancer outcomes. Journal of Clinical Oncology. 31: 5511-5511. DOI: 10.1200/Jco.2013.31.15_Suppl.5511 |
0.343 |
|
| 2012 |
Hammerman PS, Voet D, Lawrence MS, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, Getz G, Imielinski M, Helman E, Hernandez B, Pho NH, ... ... Cherniack AD, et al. Comprehensive genomic characterization of squamous cell lung cancers Nature. 489: 519-525. PMID 22960745 DOI: 10.1038/Nature11404 |
0.427 |
|
| 2012 |
Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu YQ, ... ... Cherniack AD, et al. Comprehensive molecular characterization of human colon and rectal cancer Nature. 487: 330-337. PMID 22810696 DOI: 10.1038/Nature11252 |
0.423 |
|
| 2012 |
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, ... ... Cherniack AD, et al. Comprehensive molecular portraits of human breast tumours Nature. 490: 61-70. DOI: 10.1038/Nature11412 |
0.401 |
|
| 2011 |
Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Research. 71: 7587-96. PMID 22001862 DOI: 10.1158/0008-5472.Can-11-0821 |
0.362 |
|
| 2011 |
Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proceedings of the National Academy of Sciences of the United States of America. 108: 13379-86. PMID 21788502 DOI: 10.1073/Pnas.1110104108 |
0.315 |
|
| 2009 |
Klarlund JK, Cherniack AD, McMahon M, Czech MP. P-63: Activation of the Raf/Mitogen-activated protein kinase pathway is not sufficient for disassembly of Grb2/Sos or p21ras desensitization Experimental and Clinical Endocrinology & Diabetes. 104: 128-129. DOI: 10.1055/S-0029-1211606 |
0.726 |
|
| 2006 |
Powelka AM, Seth A, Virbasius JV, Kiskinis E, Nicoloro SM, Guilherme A, Tang X, Straubhaar J, Cherniack AD, Parker MG, Czech MP. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes Journal of Clinical Investigation. 116: 125-136. PMID 16374519 DOI: 10.1172/Jci26040 |
0.745 |
|
| 2001 |
Bose A, Cherniack AD, Langille SE, Nicoloro SMC, Buxton JM, Park JG, Chawla A, Czech MP. Gα11 signaling through ARF6 regulates F-actin mobilization and GLUT4 glucose transporter translocation to the plasma membrane Molecular and Cellular Biology. 21: 5262-5275. PMID 11438680 DOI: 10.1128/Mcb.21.15.5262-5275.2001 |
0.739 |
|
| 2001 |
Mohr G, Rennard R, Cherniack AD, Stryker J, Lambowitz AM. Function of the Neurospora crassa mitochondrial tyrosyl-tRNA synthetase in RNA splicing. Role of the idiosyncratic N-terminal extension and different modes of interaction with different group I introns Journal of Molecular Biology. 307: 75-92. PMID 11243805 DOI: 10.1006/Jmbi.2000.4460 |
0.512 |
|
| 2000 |
Iwanishi M, Czech MP, Cherniack AD. The protein-tyrosine kinase Fer associates with signaling complexes containing insulin receptor substrate-1 and phosphatidylinositol 3-kinase Journal of Biological Chemistry. 275: 38995-39000. PMID 11006284 DOI: 10.1074/Jbc.M006665200 |
0.544 |
|
| 1996 |
Klarlund JK, Cherniack AD, McMahon M, Czech MP. Role of the Raf/mitogen-activated protein kinase pathway in p21(ras) desensitization Journal of Biological Chemistry. 271: 16674-16677. PMID 8663295 DOI: 10.1074/Jbc.271.28.16674 |
0.736 |
|
| 1995 |
Cherniack AD, Klarlund JK, Conway BR, Czech MP. Disassembly of Son-of-sevenless proteins from Grb2 during p21ras desensitization by insulin. The Journal of Biological Chemistry. 270: 1485-8. PMID 7829473 DOI: 10.1074/Jbc.270.4.1485 |
0.735 |
|
| 1995 |
Klarlund JK, Cherniack AD, Czech MP. Divergent mechanisms for homologous desensitization of p21ras by insulin and growth factors Journal of Biological Chemistry. 270: 23421-23428. PMID 7559502 DOI: 10.1074/Jbc.270.40.23421 |
0.735 |
|
| 1993 |
Baltensperger K, Kozma LM, Cherniack AD, Klarlund JK, Chawla A, Banerjee U, Czech MP. Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. Science (New York, N.Y.). 260: 1950-2. PMID 8391166 DOI: 10.1126/Science.8391166 |
0.744 |
|
| 1992 |
Kämper U, Kück U, Cherniack AD, Lambowitz AM. The mitochondrial tyrosyl-tRNA synthetase of Podospora anserina is a bifunctional enzyme active in protein synthesis and RNA splicing Molecular and Cellular Biology. 12: 499-511. PMID 1531084 DOI: 10.1128/Mcb.12.2.499 |
0.481 |
|
| 1990 |
Cherniack AD, Garriga G, Kittle JD, Akins RA, Lambowitz AM. Function of Neurospora mitochondrial tyrosyl-tRNA synthetase in RNA splicing requires an idiosyncratic domain not found in other synthetases. Cell. 62: 745-55. PMID 2143700 DOI: 10.1016/0092-8674(90)90119-Y |
0.53 |
|
| Show low-probability matches. |